A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2009
At a glance
- Drugs Mifepristone (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors VGX Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 18 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 02 Sep 2007 Status change from recruiting to in progress.